Pharmaceuticals

Meganuclease Genome Editing Market to Grow at a CAGR of 17% from 2025 to 2029

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Meganuclease Genome Editing Market?

The meganuclease genome editing market has experienced swift expansion over recent years. It is anticipated to increase from $1.05 billion in 2024 to $1.23 billion in 2025, achieving a compound annual growth rate (CAGR) of 17.4%. This historic growth can be linked to a rise in regulatory approvals for gene editing solutions, advancements in delivery techniques for genome editing tools, an increase in financial backing from both government and private sectors, a growing requirement for economical gene editing treatments, and heightened interest in addressing rare and hereditary illnesses.

The meganuclease genome editing market is anticipated to experience substantial growth over the next few years, with projections indicating it will expand to $2.30 billion by 2029, achieving a compound annual growth rate (CAGR) of 17.0%. This expansion during the forecast period is primarily fueled by the increasing prevalence of genetic disorders, augmented investment in biotechnology and genetic research, the rising integration of genome editing into personalized medicine, a growing understanding of gene therapy solutions, and expanding applications in agriculture for crop enhancement. Significant trends expected in this period include technological improvements that enhance meganuclease specificity and efficiency, advancements in delivery systems designed for targeted gene editing, the evolution of high-throughput screening techniques for genome editing, innovations enabling multiplex genome editing for complex genetic traits, and progress in mitigating the off-target effects associated with meganuclease editing.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27342&type=smp

Which Drivers Are Supporting Growth Of The Meganuclease Genome Editing Market?

The future expansion of the meganuclease genome editing market is anticipated to be driven by the rising occurrence of genetic diseases. These disorders originate from alterations or mutations within an individual’s DNA, subsequently impacting typical bodily functions. The surge in genetic diseases can be attributed to a higher incidence of consanguineous marriages, which elevates the probability of inheriting such conditions. Meganuclease genome editing offers a method to make exact incisions in DNA, facilitating the correction, deletion, or replacement of faulty genes. This, in turn, allows for targeted gene therapies that exhibit reduced off-target impacts and hold promise for curing inherited ailments. As an illustration, figures from May 2024, provided by the National Health Service, a UK-based government department, indicate that roughly 17,000 individuals in England are living with sickle cell disease, an inherited blood disorder, and approximately 250 new diagnoses occur annually. Consequently, the growing prevalence of genetic diseases is a key factor propelling the expansion of the meganuclease genome editing market.

How Is The Meganuclease Genome Editing Market Classified Into Different Segments?

The meganuclease genome editing market covered in this report is segmented

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9, Transcription Activator-Like Effector Nucleases (TALENs) Or Meganuclase-Transcription Activator-Like Effector Nucleases (MegaTALs), Zinc Finger Nucleases (ZFN), Meganuclease, Other Technologies

2) By Mode: Contract, In-house

3) By Delivery Method: Ex-Vivo, In-Vivo

4) By Application: Genetic Engineering, Cell Line Engineering, Plant Genetic Engineering, Animal Genetic Engineering, Clinical Applications, Diagnostics Development, Therapy Development, Other Applications

5) By End-User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Contract Research Organizations

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 Gene Editing, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas13

2) By Transcription Activator-Like Effector Nucleases (TALENs) Or Meganuclase-Transcription Activator-Like Effector Nucleases (MegaTALs): Genome Editing Applications, Therapeutic Applications, Agricultural Biotechnology

3) By Zinc Finger Nucleases (ZFN): Zinc Finger Nucleases Gene Editing

4) By Meganuclease: Homing Endonucleases

5) By Other Technologies: Base Editing, Prime Editing

Which Ongoing Trends Are Expected To Shape The Meganuclease Genome Editing Market Outlook?

Major companies operating in the meganuclease genome editing market are concentrating on developing advanced solutions, such as in vivo gene insertion programs, to enhance therapeutic applications and expand the scope of genetic disease correction. In vivo gene insertion programs function by delivering genetic material directly into living organisms to insert or correct specific genes within their natural cells, enabling precise therapeutic interventions for treating genetic disorders inside the body. For instance, in May 2024, iECURE Inc., a US-based gene editing company, introduced ECUR-506, an in vivo gene insertion program designed to treat neonatal onset ornithine transcarbamylase (OTC) deficiency, which was granted fast track designation by the U.S. Food and Drug Administration (FDA). This specific gene editing therapy is intended for the treatment of neonatal onset ornithine transcarbamylase (OTC) deficiency. This therapy is tailored for newborn males with severe neonatal-onset OTC deficiency and aims to restore functional OTC enzyme activity via a single intravenous infusion. It has shown a complete clinical response in the first infant treated, allowing for the discontinuation of ammonia scavenger medications and a return to normal protein intake, with manageable side effects reported.

Which Industry Leaders Are Driving Innovation Across The Meganuclease Genome Editing Market?

Major companies operating in the meganuclease genome editing market are Thermo Fisher Scientific Inc., Danaher Corp., Merck KGaA, Lonza Group Ltd., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Genscript, Takara Bio Inc., Sangamo Therapeutics Inc., Horizon Discovery, Applied StemCell Inc., Intellia Therapeutics Inc., Synthego Corporation, Editas Medicine Inc., Cellectis SA., New England Biolabs, Origene Technologies, Bluebird Bio Inc., Precision Biosciences Inc., Caribou Biosciences Inc., CRISPR Therapeutics AG.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/meganuclease-genome-editing-global-market-report

Which Regional Markets Are Contributing Most To The Meganuclease Genome Editing Industry Expansion?

North America was the largest region in the meganuclease genome editing market in 2024. The regions covered in the meganuclease genome editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Meganuclease Genome Editing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27342&type=smp

Browse Through More Reports Similar to the Global Meganuclease Genome Editing Market 2025, By The Business Research Company

Business Travel Accident Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/business-travel-accident-insurance-global-market-report

Accidental Death Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/accidental-death-insurance-global-market-report

Motor Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/motor-insurance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795